OMass Therapeutics, a biopharmaceutical company using structural mass spectrometry to discover novel medicines, has announced completion of a £14 million Series A financing. New investor Syncona Ltd led the round, alongside Oxford Sciences Innovation. The financing supports development of a pipeline of drug development programmes.

Fluidic Analytics, a Cambridge-based life sciences business, has secured a £24m funding package to continue its research and development plans after launching a transformative protein analysis tool. BGF is providing £5m of growth capital in a funding round with Delin Ventures and existing shareholders including Draper Esprit and IQ Capital.

Thermetrix Ltd has secured £500,000 investment for their latest venture to support the development of a diabetic footcare system.  The funding includes £200,000 seed investment from the Development Bank of Wales as well as business angels and corporate support.

The equity investment, which has come from the Wales Technology Seed Fund, will also back the launch of Podium, for both home and professional use, working with nursing homes, podiatrists and other medical professionals.

Established in 2018, Thermetrix, based in Abercynon is working with a team of experts to produce Podium, giving people with diabetes an easy and fast way to check the soles of their feet and seek earlier intervention from their healthcare team to prevent further complications. Using thermal imaging technology, the system can be used to take a daily image of their feet which can then be shared with their podiatrist or GP through a cloud-based dashboard app.

The Riverside Company has signed a definitive agreement to sell its investment in Euromed Botanicals S.A. to Dermapharm Holding SE. Barcelona-based Euromed provides standardized herbal extracts and natural active substances for the pharmaceutical, dietary supplement and cosmetic industries. The transaction is expected to close in the next few months upon receipt of antitrust approval. 

Inovus Medical, a leading designer and manufacturer of medical and surgical simulators, has announced the successful completion of a £500,000 investment from NPIF - Mercia Equity Finance, which is managed by Mercia Fund Managers and part of the Northern Powerhouse Investment Fund.

The investment is part of a £700,000 investment round alongside an angel investor and will help to create four new jobs, accelerating the growth of Inovus Medical’s commercial operations in the domestic and international markets.

The company also plans to utilise the funding to add a suite of new 3D printing technologies to its manufacturing processes and introduce new software additions to its existing product offering.

Albion Capital, the leading independent investment manager, has invested £5 million in The Evewell, a fully-integrated centre of medical excellence dedicated to caring for and protecting all aspects of fertility and gynaecological health.  The centre, which opened on Harley Street in London this month, focuses on both gynaecology and reproductive health to ensure that fertility patients receive the most appropriate treatment and advice to maximise their prospects of conceiving. It offers a fully integrated suite of women’s health services that differentiates it from other clinics. The clinic is equipped with the latest technologies for screening and treatment, and is set in a discreet and luxurious environment that provides a best-in-class service.

FreeOx Biotech, a spin-out of Hospital Clinic Barcelona-IDIBAPS created in 2017 that is developing a new class of neuroprotective drugs, has closed its first round of funding with €500,000 from private investors Montserrat Esteve and Francisco Javier Alsina.

Mercia Technologies investment Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.

The TEPI Patch was shown to be well tolerated by all subjects in a study of skin irritation and sensitisation. This marks the first clinical safety evaluation of Medherant’s novel adhesive, facilitating the development of the next generation of drug-in-adhesive patches.

Suffolk-based biotechnology company, PBD Biotech Ltd, has announced that its key technology patent has been granted by the European Patent Office, covering its Actiphage technology that allows the sensitive and specific detection of live bacteria within six hours.

Maven Capital Partners has led the management buyout of Acton Banks Limited, a market leading UK healthcare staffing business. The transaction is Maven’s third investment from its buyout fund, having earlier this year led an investment in Manchester-based hardware designer and supplier UAP Limited and Glasgow-based John McGavigan Limited, a leader in decorative technology used in the automotive sector.

Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund.

Master Investor's "Investing in the age of Longevity" takes place on 1st November 2018 at the Wellcome Collection in London